A Triple-Modal Contrastive Learning Framework with Sequence, Graph, and 3D Features for Drug-Target Interaction Prediction

2026-05-28 · Source: Machine Learning · Field: Science & Research — Life Sciences & Biology, Mathematics & Computational Sciences, Artificial Intelligence & Machine Learning · Depth: Expert, quick

Summary

TriMod-DTI is a novel triple-modal contrastive learning framework designed to enhance drug-target interaction (DTI) prediction, a critical step in drug discovery. Addressing the limitations of existing single or dual-modal methods that often overlook 3D structural features, TriMod-DTI integrates 1D sequences, 2D graphs, and 3D structures of both drugs and proteins. The framework employs a Feature Extractor to capture rich, multi-modal representations and utilizes a triple-modal contrastive learning strategy. This strategy aligns diverse modal representations of the same drug or protein in a latent space by constructing cross-modal positive and negative sample pairs, thereby boosting the model's discriminative power. Experiments on three benchmark datasets confirm TriMod-DTI's superior performance over state-of-the-art methods, with ablation studies validating each modality's contribution and case studies demonstrating its practical utility.

Key takeaway

For Research Scientists developing DTI prediction models, TriMod-DTI's success with triple-modal contrastive learning suggests a critical shift. You should consider integrating 1D sequence, 2D graph, and 3D structural data to overcome limitations of single or dual-modal approaches. This method offers a path to significantly improve prediction accuracy and accelerate drug discovery pipelines.

Key insights

TriMod-DTI uses triple-modal contrastive learning with 1D, 2D, and 3D features for superior drug-target interaction prediction.

Principles

• Integrating 1D, 2D, and 3D features enriches representations.
• Contrastive learning aligns multi-modal data in latent space.
• Cross-modal pairing enhances discriminative model ability.

Method

TriMod-DTI extracts drug/target features across 1D sequences, 2D graphs, and 3D structures. It then applies a triple-modal contrastive learning strategy to align these representations using cross-modal positive/negative pairs.

In practice

• Apply multi-modal feature extraction for complex biological data.
• Use contrastive learning to fuse disparate data types.
• Enhance DTI prediction accuracy in drug discovery.

Topics

• Drug-Target Interaction
• Contrastive Learning
• Multi-modal Learning
• Drug Discovery
• Protein Structure Prediction
• Graph Neural Networks

Best for: AI Scientist, Machine Learning Engineer, Research Scientist

Related on AIssential

• Co-Diffusion: An Affinity-Aware Two-Stage Latent Diffusion Framework for Generalizable Drug-Target Affinity Prediction — Co-Diffusion enhances drug-target affinity prediction in cold-start scenarios using a two-stage, affinity-aware latent diffusion framework.
• Learning Emergent Modular Representations in Multi-modality Medical Vision Foundation Models — DEX uses modular networks with experts and a director to manage modality-specific and shared representations in multi-modality medical FMs.
• GraphDiffMed: Knowledge-Constrained Differential Attention with Pharmacological Graph Priors for Medication Recommendation — Combining dual-scale differential attention with pharmacological graph priors significantly enhances medication recommendation safety and quality.
• REVEAL: Multimodal Vision-Language Alignment of Retinal Morphometry and Clinical Risks for Incident AD and Dementia Prediction — Jointly modeling retinal images and clinical risk factors via VLM improves early AD and dementia prediction.
• Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation — MIDAS, a multimodal GNN, effectively identifies novel immuno-oncology targets by integrating diverse biological data.
• Predicting and interpreting cell-type-specific drug responses in the small-data regime using inductive priors — PrePR-CT uses graph-based deep learning with cell-type-specific co-expression networks to predict drug responses in data-limited settings.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Machine Learning.